SFM
GLUE icon

Sphera Funds Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Sphera Funds Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-118,103
Closed -$626K – 119
2024
Q3 		$626K Sell
118,103
-256,897
-69% -$1.3M 0.1% 106
2024
Q2 		$1.4M Buy
+375,000
New +$1.91M 0.19% 97
2024
Q1 		– Sell
-48,511
Closed -$274K – 113
2023
Q4 		$274K Buy
+48,511
New +$190K 0.04% 95
2021
Q4 		– Sell
-119,647
Closed -$2.67M – 107
2021
Q3 		$2.67M Buy
119,647
+19,647
+20% +$563K 0.22% 88
2021
Q2 		$2.27M Buy
+100,000
New +$2.04M 0.15% 105

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sphera Funds Management's GLUE Position: Q4 2024 in Review

Sphera Funds Management sold out of Monte Rosa Therapeutics (GLUE) in Q4 2024, closing a stake of 118,103 shares — an estimated $626K sold.

Sphera Funds Management first reported a position in GLUE in Q2 2021 and held it in 5 quarters. The position peaked at $2.67M in Q3 2021. 104 funds tracked by Wall St. Rank hold GLUE as of Q4 2024.

  • Sphera Funds Management reported no remaining Monte Rosa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sphera Funds Management sold 118,103 Monte Rosa Therapeutics shares in Q4 2024, an estimated $626K.
  • Sphera Funds Management first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 5 quarters.
  • Sphera Funds Management's Monte Rosa Therapeutics position peaked at $2.67M in Q3 2021.
  • 104 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2024.

Based on Sphera Funds Management's 13F filing for Q4 2024, filed 14 Feb 2025.